{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:49:20Z","timestamp":1784130560171,"version":"3.55.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pioglitazone is a thiazolidinedione (TZD) insulin sensitizer approved for use in human type 2 diabetes mellitus. Therapeutic options for diabetes in cats are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effects of pioglitazone in obese cats, which are predisposed to insulin resistance, to assess its potential for future use in feline diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>A total of 12 obese purpose-bred research cats (6 neutered males and 6 spayed females, 5\u20137 years of age, weighing 5.4\u20139.8 kg).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Randomized, placebo-controlled 3-way crossover study. Oral placebo or pioglitazone (Actos\u2122; 1 or 3 mg\/kg) was administered daily for 7-week periods, with IV glucose tolerance testing before and after each period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three mg\/kg pioglitazone significantly improved insulin sensitivity (geometric mean [95% CI] 0.90 [0.64\u20131.28] to 2.03 [1.49\u20132.78] min \u22121pmol\u22121L; P = .0014 versus change with placebo), reduced insulin area under the curve during IVGTT (geometric mean [range] 27 [9\u201364] to 18 [6\u201354] min\u2219nmol\/L; P = .0031 versus change with placebo), and lowered serum triglyceride (geometric mean [range] 71 [29\u2013271] to 48 [27\u201375] mg\/dL; P = .047 versus change with placebo) and cholesterol (geometric mean [range] 187 [133\u2013294] to 162 [107\u2013249] mg\/dL; P = .0042 versus change with placebo) concentrations in the obese cats. No adverse effects attributable to pioglitazone were evident in the otherwise healthy obese cats at this dosage and duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Results of this study support a positive effect of pioglitazone on insulin sensitivity and lipid metabolism in obese cats, and suggest that further evaluation of the drug in cats with diabetes mellitus or other metabolic disorders might be warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.12255","type":"journal-article","created":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T17:12:25Z","timestamp":1385399545000},"page":"166-174","source":"Crossref","is-referenced-by-count":11,"title":["Effects of Pioglitazone on Insulin Sensitivity and Serum Lipids in Obese Cats"],"prefix":"10.1093","volume":"28","author":[{"given":"M.","family":"Clark","sequence":"first","affiliation":[{"name":"University of Illinois, College of Veterinary Medicine Department of Comparative Biosciences, , Urbana, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Thomaseth","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering \u2014 ISIB, CNR \u2014 National Research Council of Italy , Padova,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dirikolu","sequence":"additional","affiliation":[{"name":"University of Illinois, College of Veterinary Medicine Department of Comparative Biosciences, , Urbana, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. C.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"University of Illinois, College of Veterinary Medicine Department of Comparative Biosciences, , Urbana, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hoenig","sequence":"additional","affiliation":[{"name":"University of Illinois, College of Veterinary Medicine Department of Veterinary Clinical Medicine, , Urbana, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,1]]},"reference":[{"key":"2026020304342484200_jvim12255-bib-0001","first-page":"1796","volume-title":"Textbook of Veterinary Internal Medicine","author":"Reusch","year":"2010"},{"key":"2026020304342484200_jvim12255-bib-0002","first-page":"R227","article-title":"Insulin sensitivity, fat distribution, and adipocytokine response to different diets in lean and obese cats before and after weight loss","volume":"292","author":"Hoenig","year":"2007","journal-title":"Am J Physiol Reg I"},{"key":"2026020304342484200_jvim12255-bib-0003","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1939-1676.2010.0579.x","article-title":"Evaluation of a Quality-of-Life tool for cats with diabetes mellitus","volume":"24","author":"Niessen","year":"2010","journal-title":"J Vet Intern Med"},{"key":"2026020304342484200_jvim12255-bib-0004","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/S0002-9440(10)64852-3","article-title":"A feline model of experimentally induced islet amyloidosis","volume":"157","author":"Hoenig","year":"2000","journal-title":"Am J Pathol"},{"key":"2026020304342484200_jvim12255-bib-0005","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"New Engl J Med"},{"key":"2026020304342484200_jvim12255-bib-0006","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1210\/jc.2009-0911","article-title":"Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus","volume":"95","author":"Bajaj","year":"2010","journal-title":"J Clin Endocr Metab"},{"key":"2026020304342484200_jvim12255-bib-0007","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.amjmed.2009.12.008","article-title":"Overview of newer agents: Where treatment is going","volume":"123","author":"DeFronzo","year":"2010","journal-title":"Am J Med"},{"key":"2026020304342484200_jvim12255-bib-0008","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2460\/ajvr.2003.64.1409","article-title":"Effect of darglitazone on glucose clearance and lipid metabolism in obese cats","volume":"64","author":"Hoenig","year":"2003","journal-title":"Am J Vet Res"},{"key":"2026020304342484200_jvim12255-bib-0009","volume-title":"Actos Label, August 4, 2011","author":"U.S. Food and Drug Administration Center for Drug Evaluation and Research"},{"key":"2026020304342484200_jvim12255-bib-0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.domaniend.2006.04.003","article-title":"Fatty acid turnover, substrate oxidation, and heat production in lean and obese cats during the euglycemic hyperinsulinemic clamp","volume":"32","author":"Hoenig","year":"2006","journal-title":"Domest Anim Endocrin"},{"key":"2026020304342484200_jvim12255-bib-0011","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2460\/ajvr.2002.63.634","article-title":"Effect of neutering on hormonal concentrations and energy requirements in male and female cats","volume":"63","author":"Hoenig","year":"2002","journal-title":"Am J Vet Res"},{"key":"2026020304342484200_jvim12255-bib-0012","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2885.2011.01341.x","article-title":"Pharmacokinetics of pioglitazone in lean and obese cats","volume":"35","author":"Clark","year":"2012","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020304342484200_jvim12255-bib-0013","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2460\/ajvr.2004.65.1090","article-title":"Assessment of the influence of fatty acids on indices of insulin sensitivity and myocellular lipid content by use of magnetic resonance spectroscopy in cats","volume":"65","author":"Wilkins","year":"2004","journal-title":"Am J Vet Res"},{"key":"2026020304342484200_jvim12255-bib-0014","first-page":"E667","article-title":"Quantitative estimation of insulin sensitivity","volume":"236","author":"Bergman","year":"1979","journal-title":"Am J Physiol Endoc M"},{"key":"2026020304342484200_jvim12255-bib-0015","first-page":"21","volume-title":"Mathematical Modeling in Nutrition and Toxicology","author":"Thomaseth","year":"2005"},{"key":"2026020304342484200_jvim12255-bib-0016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0169-2607(02)00095-0","article-title":"Multidisciplinary modeling of biological systems","volume":"71","author":"Thomaseth","year":"2003","journal-title":"Comput Methods Programs Biomed"},{"key":"2026020304342484200_jvim12255-bib-0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1464-5491.1999.00023.x","article-title":"Thiazolidinediones: A new class of antidiabetic drugs","volume":"16","author":"Day","year":"1999","journal-title":"Diabetic Med"},{"issue":"1","key":"2026020304342484200_jvim12255-bib-0018","first-page":"156","article-title":"Effects of pioglitazone on glucose and lipid metabolism in normal and insulin-resistant animals","volume":"40","author":"Ikeda","year":"1990","journal-title":"Arzneimittel-Forsch"},{"key":"2026020304342484200_jvim12255-bib-0019","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diacare.23.1.64","article-title":"Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects","volume":"23","author":"Frias","year":"2000","journal-title":"Diabetes Care"},{"key":"2026020304342484200_jvim12255-bib-0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/CS20110662","article-title":"Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein \u03b2 up-regulation","volume":"123","author":"Powell","year":"2012","journal-title":"Clin Sci"},{"key":"2026020304342484200_jvim12255-bib-0021","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2460\/javma.1996.209.05.943","article-title":"Pretreatment clinical and laboratory evaluation of cats with diabetes mellitus: 104 cases (1992\u20131994)","volume":"209","author":"Crenshaw","year":"1996","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304342484200_jvim12255-bib-0022","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.domaniend.2008.05.008","article-title":"Dyslipidemia in obese cats","volume":"35","author":"Jordan","year":"2008","journal-title":"Domest Anim Endocrin"},{"key":"2026020304342484200_jvim12255-bib-0023","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.mco.0000241668.30761.69","article-title":"The cat as a model for human nutrition and disease","volume":"9","author":"Hoenig","year":"2006","journal-title":"Curr Opin Clin Nutr"},{"key":"2026020304342484200_jvim12255-bib-0024","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.2337\/diabetes.50.5.1158","article-title":"Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability","volume":"50","author":"Oakes","year":"2001","journal-title":"Diabetes"},{"key":"2026020304342484200_jvim12255-bib-0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1046\/j.1463-1326.2003.00268.x","article-title":"Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI\/S studies in Zucker fatty rats","volume":"5","author":"Hockings","year":"2003","journal-title":"Diabetes Obes Metab"},{"key":"2026020304342484200_jvim12255-bib-0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02581007","article-title":"Exploration of the early insulin response by two small successive loads of IV glucose in normal and obese subjects","volume":"15","author":"Prando","year":"1978","journal-title":"Acta Diabetol Lat"},{"key":"2026020304342484200_jvim12255-bib-0027","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF02590749","article-title":"IV glucose tolerance test: Correlation between FFA, glucose and IRI in normal, obese, and diabetic subjects","volume":"15","author":"Prando","year":"1978","journal-title":"Acta Diabetol Lat"},{"key":"2026020304342484200_jvim12255-bib-0028","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ejcn.2012.98","article-title":"Intravenous acetate elicits a greater free fatty acid rebound in normal than hyperinsulinaemic humans","volume":"66","author":"Fernandes","year":"2012","journal-title":"Eur J Clin Nutr"},{"key":"2026020304342484200_jvim12255-bib-0029","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI200523219","article-title":"Effects of the PPAR\u03b3 agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus","volume":"155","author":"Nagashima","year":"2005","journal-title":"J Clin Invest"},{"key":"2026020304342484200_jvim12255-bib-0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF00368097","article-title":"Lipoprotein metabolism in dogs and cats","volume":"6","author":"Watson","year":"1996","journal-title":"Comp Haematol Int"},{"key":"2026020304342484200_jvim12255-bib-0031","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1939-1676.2010.0598.x","article-title":"Predictors of clinical remission in cats with diabetes mellitus","volume":"24","author":"Zini","year":"2010","journal-title":"J Vet Intern Med"},{"key":"2026020304342484200_jvim12255-bib-0032","doi-asserted-by":"crossref","first-page":"2747S","DOI":"10.1093\/jn\/128.12.2747S","article-title":"Characterization of serum lipoprotein profiles of healthy, adult cats and feline hepatic lipidosis patients","volume":"128","author":"Pazak","year":"1998","journal-title":"J Nutr"},{"key":"2026020304342484200_jvim12255-bib-0033","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","article-title":"Adiponectin: Mechanistic insights and clinical implications","volume":"55","author":"Turer","year":"2012","journal-title":"Diabetologia"},{"key":"2026020304342484200_jvim12255-bib-0034","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.2337\/diabetes.50.9.2094","article-title":"PPAR\u03b3 ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein","volume":"50","author":"Maeda","year":"2001","journal-title":"Diabetes"},{"key":"2026020304342484200_jvim12255-bib-0035","doi-asserted-by":"crossref","first-page":"8748","DOI":"10.1074\/jbc.M505649200","article-title":"Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and \u2013independent pathways","volume":"281","author":"Kubota","year":"2006","journal-title":"J Biol Chem"},{"key":"2026020304342484200_jvim12255-bib-0036","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2004.07.008","article-title":"Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial","volume":"54","author":"Smith","year":"2005","journal-title":"Metabolism"},{"key":"2026020304342484200_jvim12255-bib-0037","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2337\/dc09-1600","article-title":"Effect of pioglitazone on energy intake and ghrelin in diabetic patients","volume":"33","author":"Martin","year":"2010","journal-title":"Diabetes Care"},{"key":"2026020304342484200_jvim12255-bib-0038","volume-title":"Actos Drug Approval Package, Pharmacology Reviews, Part 2, June 30, 1999","author":"U.S. Food and Drug Administration Center for Drug Evaluation and Research"},{"key":"2026020304342484200_jvim12255-bib-0039","volume-title":"Actos Drug Approval Package, Pharmacology Reviews, Part 6, June 30, 1999","author":"U.S. Food and Drug Administration Center for Drug Evaluation and Research"},{"key":"2026020304342484200_jvim12255-bib-0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/01.ATV.0000195790.24531.4f","article-title":"Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with the metabolic syndrome","volume":"26","author":"Szapary","year":"2006","journal-title":"Arterioscl Throm Vas"},{"key":"2026020304342484200_jvim12255-bib-0041","volume-title":"Actos: European Public Assessment report-scientific discussion, 2004","author":"European Medicines Agency"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.12255","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.12255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/28\/1\/166\/66686015\/jvim12255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/28\/1\/166\/66686015\/jvim12255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:34:58Z","timestamp":1770111298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/28\/1\/166\/8452141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.12255","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,1]]},"published":{"date-parts":[[2014,1,1]]}}}